Polypeptide

Details Polypeptide Polypeptide

2005-11-22

2009-10-13

Yaen, Christopher H (Department: 1643)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

Reexamination Certificate

active

07601698

ABSTRACT:
The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use thereof in vaccinating against and in treating tumours.

REFERENCES:
patent: 4558035 (1985-12-01), Johnson
patent: 5118672 (1992-06-01), Schinazi et al.
patent: 5869053 (1999-02-01), Stem et al.
patent: 5962274 (1999-10-01), Parks
patent: 2004/0081656 (2004-04-01), Myers et al.
patent: 2004/0131591 (2004-07-01), Kingsman et al.
patent: 0110385 (1984-06-01), None
patent: 0198328 (1986-10-01), None
patent: WO 89/07947 (1989-09-01), None
patent: WO 92/03568 (1992-03-01), None
patent: WO 97/19183 (1997-05-01), None
patent: WO99/15683 (1999-04-01), None
patent: WO99/15684 (1999-04-01), None
Orkin and Motulsky (NIH ad hoc committee Dec. 1995—http://www.nih.gov
ews/panelrep.html).
Theodore Friedmann (scientific American Jun. 1997, p. 96-101).
Inder Verma et al (Nature Sep. 1997;389:239-242).
Rubanyi GM (Molecular Aspects of Medecine 2001;22:113-142).
Perkins, David L., et al. “Immunodominance: Intramolecular Competition Between T-Cell Epitopes”,J. Immunol. (1997) 146(7):2137-2144.
Theobald, Matthias, et al. “The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells from Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope”,J. Exp. Med. (1998) 188(6):1017-1028.
Gileadi, Uzi, et al. “Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes”,Eur. J. Immunol. (1999) 29:2213-2222.
Engelhard, Victor H. “Structure of peptides associated with MHC class 1 molecules”,Current Opinion in Immunology(1994) 6:13-23.
Eisenlohr, Laurence C., et al. “Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes”,J. Exp. Med. (1992) 175:481-487.
Shastri, Nilbah, et al. “Presentation of Endogenous Peptide/MHC Class I Complexes is Profoundly Influenced by Specific C-Terminal Flanking Residues”,J. Immunol. (1995) 155:4339-4346.
Bergmann, Cornelia C., et al. “Differential Effects of Flanking Residues on Presentation of Epitopes from ChImeric Peptides”,J. Virol. (1994) 68(8):5306-5310.
Wang, Yusheng, et al. “Silencing of Immunodominant Epitopes by Contiguous Sequences in Complex Synthetic Peptides”,Cell Immunol. (1992) 143:284-297.
Celis, Esteban, et al. “Identification of Potential CTL Epitopes of Tumor-Associated Antigen Mage-1 for Five Common HLA-A Alleles”,Molec.Immunol.(1994) 31(18):1423-1430.
Guo, Hwai-Chen. et al. “Different length peptides bind to HLA-Aw68 similarity at their ends but bulge out in the middle”,Nature(1992) 360:364-366.
Ochoa-Garay, Jorge, et al. “The Ability of Peptides to Induce Cytotoxic T Cells In Vitro Does Not Strongly Correlate With Their Affinity for H-2LdMolecule: Implications for Vaccine Design and Immunotherapy”,Molec. Immunol. (1997) 34(3):273-281.
Chaux, Pascal, et al. “Estimation of the Frequencies of Anti-Mage-3 Cytolytic T-Lymphocyte Precursors in Blood From Individuals Without Cancer”,Int. J. Cancer(1998) 77:538-542.
GenEmbl Accession No. Z29083 (1998).
Stern, Peter, et al. “Characterization of the Human Trophoblast-Leukocyte Antigenic Molecules Defined by a Monoclonal Antibody”,The Journal of Immunology(1986) 137(5):1604-1609.
Johnson, P.M., et al. Human Trophoblast-Specific Surface Antigens Identified Using Monoclonal Antibodies,American Journal of Reproductive Immunology(1981) 1:246-254.
Rettig, Wolfgang J., et al. “Cell Surface Antigens of Human Trophoblast and Choriocarcinoma Defined by Monoclonal Antibodies”,Int. J. Cancer(1985) 35:469-475.
Hole, M., et al. “Trophoblast-Specific Glycoprotein Defined by Monoclonal Antibody 5T4”,British Society for Immunology&British Transplantation Society 1986 Joint Annual Meeting. Nov. 12-14, 1986, abstract 66.
Stern, P.L. et al. “Molecular Characterisation of Human Terato-Carcinoma-Trophoblast Cell Surface Antigens”,J. Repro. Immun., Supp: (Jun. 6, 1986).
Anderson, Deborah J., et al. Monoclonal antibodies to human trophoblast and sperm antigens: Report of two WHO sponsored workshops, Jun. 30, 1986—Toronto, CanadaJ. Repro. Immun. (1987) 10:231-257.
Cho, S.-W., et al. “Characterization of three monoclonal antibodies to membrane co-factor protein (MCP) of the complement system and quantification of MCP by radioassay”,Clin. Exp. Immunol. (1991) 83:257-261.
Purcell, D.F.J., et al., “The human cell-surface glycoproteins HuLy-m5, membrane co-factor protein (MCP) of the complement system, and trophoblast leucocyte-common (TLX) antigen, are CD46”,Immunology(1990) 70:155-161.
Coulie P. “Human Tumor Antigens Recognization by Cytolytic T Lymphocytes”, Chapter 5, pp. 95-125,Tumor Immunology, Eds. Daglelsh & Browning, Cambridge University Press 1996.
Rosenkrantz, K., et al. “Generation and regulation of autocytotoxicity in mixed lymphocyte cultures: Evidence for active suppression of autocytotoxic cells”,PNAS(1985) 82:4508-4512.
Stavely-O'Carroll, et al. “Induction of antigen-specific T cell energy: An early event in the course of tumor progression”,PNAS(1998) 95:1178-1183.
Manson, L, et al. “Short Analytical Review—Anti-tumor Immune Responses of the Tumor Bearing Host: The Case for Antibody-Mediated Immunologic Enhancement ”,Clinical Immunology&Immunopathology(1994) 72(1):1-8.
Ganss, R., et al. “Tumor Microenvironment Can Restrict the Effectiveness of Activated Antitumor Lymphocytes”,Cancer Research(1998) 58:4673-4681.
Berd, D. “Cancer Vaccines: Reborn or Just Recycled?”,Seminars in Oncology(1998) 25(6):605-610.
Hersey, P., et al. “Impediments to Successful Immunotherapy”,Pharmcol. Ther. (1999) 81(2):111-119.
Takahashi, K., et al. “Escape Mechanisms of Melanoma From Immune System by Soluble Melanoma Antigen”,The Journal of Immunology(1988) 140(9):3244-3248.
Janeway & Travers,Immunobiology: The Immune System in Health and Disease, Third edition, Current Biology Ltd./Garland Publishing Inc. (1997).
Amato, R., et al. Phase II Trial to Assess the Activity of MVA 5T4 (Trovax®) alone versus MVA 5T4 plus Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF) in Patients (pts) with Progressive Hormone Refractory Prostate Cancer (HRPC), Abstract, 18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”, Nov. 7-10, 2006, Prague, Czech Republic.
Amato, R., et al. Activity of MVA 5T4 alone or in Combination with either Interleukin-2 (IL-2), Interferon-α (IFN), or Sunitinib in Patients (Pts) with Metastatic Renal Cell Cancer (MRCC), Abstract, 18th EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”, Nov. 7-10, 2006, Prague, Czech Republic.
Sykulev, Y., et al. “Evidence that a Single Peptide-MHC Complex on a Target Cell Can Elicit a Cytolytic T Cell Response”,Immunity(1996) 4:565-571.
Guschlbauer, et al. “Poly-2′-deoxy-2′-fluoro-cytidylic acid: enzymatic synthesis, spectroscopic characterization and interaction with poly-inosinic acid”,Nucleic Acids Res. (1977) 4:1933.
Schibahara, et al. “Site-directed cleavage of RNA”,Nucleic Acids Res. (1987) 15:4403.
Gershon, et al. “The nucleotide sequence aorund the capripoxvirus thymidine kinase gene reveals a gene shared specifically with leporipoxvirus”,J. Gen. Virol, (1989) 70:525.
Weir, et al. “Nucleotide sequence of the vaccinia virus thymidine kinase gene and the nature of spontaneous frameshift mutations”,J. Virol. (1983) 46:530.
Esposito, et al. “Nucleotide sequence of the thymidine kinase gene reg

Affiliated with

Also associated with

Rating

Polypeptide does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polypeptide, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polypeptide will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4104718